Colorado regulates MAC-list sourcing and transparency and provides a robust appeal — 21 days to file, 21 days to resolve — but § 10-16-122.6 does not require reimbursement at NADAC or above acquisition cost. Drugs on a MAC list must be “generally available for purchase” from a national or regional wholesaler in the state.
Separately, Colorado has enacted a reform (HB 1094) that moves PBM compensation toward a flat-fee model effective 2027 — a different approach to the problem than a NADAC reimbursement floor.